Showing 681-690 of 7756 results for "".
DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acTalking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Tips on Expanding Your Practice Focus to Men
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-on-expanding-your-practice-focus-to-men/18699/“I see the male patient as a huge opportunity I think men have been largely overlooked,” says Terrence Keaney, MD. He explains what procedures and services appeal to men, talks about the fundamentals of building a male-friendly practice, and offers tips to make male patients more comfortable undergoTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?Laser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.Overcoming Challenges in Topical Psoriasis Care
https://practicaldermatology.com/topics/psoriasis/overcoming-challenges-in-topical-psoriasis-care/18685/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for palmar plantar psoriasis and the combined use of topical corticosteroids with phototherapy. They also address alternative topical agents like topical immunomodulators.Allergan Board Rejects Latest Valeant Bid; Topical Jublia Approved for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dwtv-6-12/19122/Allergan's board rejects the latest merger proposal from Valeant and the FDA approves topical Jublia for onychomycosis. LEarn about these developments and hear from the AMA's new president in this edition of DermWireTV.Vitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.ASDS: Dr. Farah on Hair Loss Treatment Options
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-farah-hair-regrowth-options/29152/Ronda Farah, MD, discusses treatment options for hair loss, including platelet-rich plasma and lasers, at the 2024 American Society for Dermatologic Surgery Annual Meeting.Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of its